



165 – 10551 Shellbridge Way

Richmond, BC, V6X 2W8

## **BIOMARK APPOINTS DR. JEAN-FRANCOIS HAINCE AS STRATEGIC ADVISOR TO GUIDE ITS EXPANSION INTO QUEBEC**

**Vancouver, British Columbia – (September 16th, 2020)** – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Jean-Francois (Jeff) Haince as a strategic advisor to its management team.

Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Haince into our advisory team. Jeff brings a pragmatic perspective to our bench strength along with a thorough understanding of engaging within the vibrant biotech ecosystem in Quebec and North America. Jeff’s business and product development expertise with diverse medical, scientific, and business experience applied to strategic planning and innovation management in both academia and biotech industry are important for commercialization of BioMark’s disruptive cancer assays. Jeff possesses a good understanding of the whole value chain and regulatory landscape in the pharmaceutical/healthcare industry and played a vital role in the commercialization of 2 early cancer detection molecular diagnostics.”

### **About Dr. Jean-Francois Haince**

Dr. Haince holds a PhD in Cellular and Molecular Biology from the Faculty of Medicine at Université Laval. He cumulates over 15 years of experience in cancer research and authored over 20 peer-reviewed scientific publications. During his term at DiagnoCure from 2007 to 2015, he has been responsible for the development of new molecular diagnostic tests from product design to clinical validation. Dr. Haince currently manages a multidisciplinary team of experts at SOVAR, providing advice and project management support to development and deployment of technological innovations stemming from cutting-edge research. He also sits on the Research and Innovation Committee at the l’Institut National du Sport du Québec, advising the Institut’s scientific director on all issues related to its scientific and technical activities.

### **About BioMark Diagnostics Inc.**

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website [www.sedar.com](http://www.sedar.com) and on the CSE website <https://thecse.com/>.

**For further information on BioMark, please Contact:**

Rashid Ahmed Bux  
President & CEO  
BioMark Diagnostics Inc.  
Tel. 604-370-0779  
Email: [info@biomarkdiagnostics.com](mailto:info@biomarkdiagnostics.com)

**Forward-Looking Information:**

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

**The CSE has not reviewed, approved or disapproved the content of this press release.**